She is the CEO of the company. She received her Ph.D. in Sciences from “Université Libre de Bruxelles” in 2012 under the supervision of Prof. Ivan Jabin. Her research was focused on the development of the X4C technology. She has a scientific expertise in the two domains that are useful for the technology (organic synthesis and surface modification). Moreover, she has followed training courses at Solvay Entrepreneurs to improve her business expertise.
He is the CSO of the company. He obtained his Ph.D. in Chemistry from the ESPCI-UPMC (Paris) in 1996 and then spent two years as a post-doctoral fellow. In 1998, he was named an assistant Professor at the University of Le Havre (France). In 2006, he joined the “Université Libre de Bruxelles” as a full Professor in the Organic Chemistry Laboratory of which he is the director. His current research interests include the synthesis and study of calixarene-based molecular receptors as well as the use of calixarenes for surface modification. 103 publications, 4 patents and 3 book chapters have been written by Prof. I. Jabin.
He is a serial medtech entrepreneur and executive with +20-year management experience in life sciences. He launched various medical technologies in the areas of cardiovascular, pulmonary, gastro-enterology, orthopedics and diabetes in key European and surrounding markets, and co-founded a biotech company. He holds a Msc. from the Solvay Business School and an MBA from the Wharton School.
She is a junior scientist of the company. She received her Master Thesis in Chemistry from “Université de Mons” in 2018 under the supervision of Prof. Sophie Laurent. Her research was focused on the development of bimodal silica nanoparticles for targeted inflammatory disorders.